Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells $51,306.08 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 1,064 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total transaction of $51,306.08. Following the completion of the transaction, the senior vice president now directly owns 4,232 shares of the company’s stock, valued at approximately $204,067.04. This represents a 20.09 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Jolanda Howe also recently made the following trade(s):

• On Friday, January 24th, Jolanda Howe sold 902 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.92, for a total value of $43,223.84.
• On Tuesday, January 7th, Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total value of $32,115.00.
• On Thursday, November 14th, Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.10, for a total value of $117,750.00.

Mirum Pharmaceuticals Stock Up 4.1 %

MIRM stock opened at $52.28 on Thursday. Mirum Pharmaceuticals, Inc. has a one year low of $23.14 and a one year high of $53.49. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The firm’s fifty day moving average is $44.49 and its 200 day moving average is $42.10. The firm has a market cap of $2.51 billion, a PE ratio of -25.88 and a beta of 0.96.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. The firm had revenue of $90.38 million for the quarter, compared to analysts’ expectations of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company’s quarterly revenue was up 89.4% on a year-over-year basis. During the same period last year, the firm earned ($0.57) EPS. On average, research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.44 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Citigroup lifted their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Leerink Partners lifted their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. HC Wainwright reiterated a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Finally, Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $57.10.

Institutional Trading of Mirum Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after buying an additional 318 shares during the period. R Squared Ltd purchased a new stake in Mirum Pharmaceuticals in the 4th quarter worth $69,000. Avanza Fonder AB acquired a new position in Mirum Pharmaceuticals during the fourth quarter worth $189,000. Y Intercept Hong Kong Ltd purchased a new position in Mirum Pharmaceuticals during the third quarter valued at $215,000. Finally, Creative Planning acquired a new stake in shares of Mirum Pharmaceuticals in the third quarter valued at about $249,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.